PMED Stock Overview
A pharmaceutical company, researches, develops, and sells medical treatments and lifestyle products in the field of women's health.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PEPTONIC medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.06 |
| 52 Week High | SEK 0.13 |
| 52 Week Low | SEK 0.05 |
| Beta | 0.18 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -27.71% |
| 33 Year Change | -95.15% |
| 5 Year Change | -92.95% |
| Change since IPO | -99.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| PMED | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | 2.2% |
| 1Y | -27.7% | 71.1% | 19.3% |
Return vs Industry: PMED underperformed the Swedish Pharmaceuticals industry which returned 54% over the past year.
Return vs Market: PMED underperformed the Swedish Market which returned 8.6% over the past year.
Price Volatility
| PMED volatility | |
|---|---|
| PMED Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.9% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: PMED has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PMED's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 32 | Erik Sundquist | www.peptonicmedical.se |
PEPTONIC medical AB (publ), a pharmaceutical company, researches, develops, and sells medical treatments and lifestyle products in the field of women's health. It offers VagiVital, a hormone-free treatment for symptoms related to vaginal atrophy, such as pain during intercourse, burning, itching, and dryness, as well as moisturizing and an oil-based intimate wash. The company also provides lifestyle consumer products under the Lunette brand.
PEPTONIC medical AB (publ) Fundamentals Summary
| PMED fundamental statistics | |
|---|---|
| Market cap | SEK 92.09m |
| Earnings (TTM) | -SEK 31.00m |
| Revenue (TTM) | SEK 40.52m |
2.3x
P/S Ratio-3.0x
P/E RatioIs PMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMED income statement (TTM) | |
|---|---|
| Revenue | SEK 40.52m |
| Cost of Revenue | SEK 20.53m |
| Gross Profit | SEK 20.00m |
| Other Expenses | SEK 51.00m |
| Earnings | -SEK 31.00m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 49.35% |
| Net Profit Margin | -76.50% |
| Debt/Equity Ratio | 6.7% |
How did PMED perform over the long term?
See historical performance and comparison